Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | PER2 | O15055 | 2/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15885015 | 0.89 | PRKAB2 (0.39) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL10973875 | 0.87 | PRKAB2 (0.38) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL1446194 | 0.82 | PRMT5 (0.38) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL1446411 | 0.80 | PRMT5 (0.37) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL6893925 | 0.80 | PER2 (0.37) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL24802723 | 0.80 | PRMT5 (0.37) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL21329587 | 0.80 | F10 (0.37) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL31126065 | 0.80 | POLB (0.40) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL824835 | 0.80 | KDM4E (0.41) | PRMT5WDR77PER2CRY2POLB | |
| SCHEMBL771561 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707861-A | 2-Substituted aminobenzothiazole compound and application thereof | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| EP-1392298-B1 | FUSED HETEROCYCLIC COMPOUNDS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070135425-A1 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7125885-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050148617-A1 | Fused heterocyclic compounds | TULARIK INC. | 2005-07-07 | — | — | US | disclosed |
| EP-1392298-A4 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6858619-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6809104-B2 | COMPRISES 6H-PYRIDO(4,3-B)CARBAZOLE-CONTAINING COMPOUNDS FOR TREATMENT OF OBESITY, EATING/ANXIETY/MOOD DISORDERS AND OTHER DISEASES MEDIATED BY G-PROTEIN-COUPLED-RECEPTORS AND MELANIN-CONCENTRATING HORMONE RECEPTORS | TULARIK INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1392298-A2 | FUSED HETEROCYCLIC COMPOUNDS | Tularik Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030176694-A1 | Fused heterocyclic compounds | AMGEN INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030023085-A1 | Fused heterocyclic compounds | TULARIK INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002089729-A2 | FUSED HETEROCYCLIC COMPOUNDS | TULARIK INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023085-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | PRMT5 1467/4885WDR77 2435/4885PER2 1475/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | PRMT5 3895/4885WDR77 3693/4885PER2 1039/4885 |
| US-20050148617-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | PRMT5 1467/4885WDR77 2435/4885PER2 1475/4885 |
| US-20030176694-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | PRMT5 1467/4885WDR77 2435/4885PER2 1475/4885 |
| US-20070135425-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | PRMT5 1467/4885WDR77 2435/4885PER2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.